SRNE - Why Sorrento Therapeutics Stock Shot 7% Higher Today
A rising stock price is the cure for any investor's glum mood. Sorrento Therapeutics (NASDAQ: SRNE) provided a big dose of this on Monday; its shares gained over 7% thanks to encouraging news from the laboratory about the company's coronavirus drug candidate.
That morning, Sorrento reported that it has reached full enrollment for its phase 1 study of that drug, Covishield. All told, 24 healthy recipients will be administered the drug, in the form of a nasal spray.
Image source: Getty Images.
For further details see:
Why Sorrento Therapeutics Stock Shot 7% Higher Today